ARS Pharmaceuticals (SPRY) Gains from Investment Securities (2020 - 2026)

ARS Pharmaceuticals has disclosed Gains from Investment Securities across 7 years of filings, most recently posting $100000.0 for Q1 2026.

• Gains from Investment Securities for Q1 2026 came in at $100000.0, up 2400.0% year-over-year; the trailing twelve-month figure through Mar 2026 was -$6.5 million (up 51.14% YoY), and the FY2025 annual result was $16.7 million, up 10.44% from the prior year.
• Gains from Investment Securities came in at $100000.0 for Q1 2026 at ARS Pharmaceuticals, up from -$6.9 million in the prior quarter.
• In the past five years, Gains from Investment Securities ranged from a high of $14.4 million in Q2 2024 to a low of -$7.9 million in Q4 2023.
• The 5-year median for Gains from Investment Securities is $1.1 million (2022), against an average of $2.4 million.
• Across the five-year window, Gains from Investment Securities slumped 116.96% in 2022 and jumped 2400.0% in 2026, its largest moves.
• ARS Pharmaceuticals' Gains from Investment Securities stood at -$1.1 million in 2022, then plunged by 622.12% to -$7.9 million in 2023, then soared by 30.38% to -$5.5 million in 2024, then fell by 25.45% to -$6.9 million in 2025, then surged by 101.45% to $100000.0 in 2026.
• The last three Gains from Investment Securities figures came in at $100000.0 (Q1 2026), -$6.9 million (Q4 2025), and $300000.0 (Q3 2025), per Business Quant data.